California State Teachers Retirement System lowered its stake in shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) by 3.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,741 shares of the company’s stock after selling 1,204 shares during the period. California State Teachers Retirement System owned approximately 0.17% of Enanta Pharmaceuticals worth $722,000 at the end of the most recent reporting period.
Several other institutional investors also recently made changes to their positions in the stock. Pacad Investment Ltd. raised its position in shares of Enanta Pharmaceuticals by 15.3% in the first quarter. Pacad Investment Ltd. now owns 9,800 shares of the company’s stock valued at $288,000 after buying an additional 1,300 shares in the last quarter. Alps Advisors Inc. raised its position in shares of Enanta Pharmaceuticals by 11.5% in the second quarter. Alps Advisors Inc. now owns 41,273 shares of the company’s stock valued at $910,000 after buying an additional 4,273 shares in the last quarter. Strs Ohio raised its position in shares of Enanta Pharmaceuticals by 19.8% in the second quarter. Strs Ohio now owns 29,000 shares of the company’s stock valued at $639,000 after buying an additional 4,800 shares in the last quarter. Royal Bank of Canada raised its position in shares of Enanta Pharmaceuticals by 40.3% in the first quarter. Royal Bank of Canada now owns 25,019 shares of the company’s stock valued at $735,000 after buying an additional 7,190 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its position in shares of Enanta Pharmaceuticals by 0.8% in the second quarter. Eagle Asset Management Inc. now owns 1,001,572 shares of the company’s stock valued at $22,084,000 after buying an additional 7,747 shares in the last quarter. Hedge funds and other institutional investors own 70.82% of the company’s stock.
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) traded down 0.94% during midday trading on Monday, hitting $26.36. 172,815 shares of the stock traded hands. The stock’s 50-day moving average price is $23.99 and its 200-day moving average price is $24.94. The stock has a market capitalization of $501.76 million, a P/E ratio of 17.43 and a beta of 0.52. Enanta Pharmaceuticals Inc. has a 52 week low of $16.75 and a 52 week high of $41.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. The business had revenue of $14 million for the quarter, compared to analyst estimates of $13.07 million. Enanta Pharmaceuticals had a net margin of 32.59% and a return on equity of 11.31%. The company’s revenue was up 20.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.13 EPS. Equities research analysts expect that Enanta Pharmaceuticals Inc. will post $1.02 EPS for the current fiscal year.
Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, July 28th. JPMorgan Chase & Co. set a $26.00 price objective on shares of Enanta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Enanta Pharmaceuticals has a consensus rating of “Hold” and an average target price of $27.24.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc. (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.